Novavax Inc (NVAX)

$10.23 -0.07 (-0.63%)
Market Cap 1.67B
Revenue (ttm) 1.12B
Net Income (ttm) 440.30M
EPS (ttm) N/A
PE Ratio 3.37
Forward PE N/A
Profit Margin 39.19%
Debt to Equity Ratio 0.00
Volume 2,859,200
Avg Vol 5,380,712
Day's Range N/A - N/A
Shares Out 162.94M
Stochastic %K 57%
Beta 2.54
Analysts Sell
Price Target $13.78

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 268 2000
Address:
700 Quince Orchard Road, Gaithersburg, United States
Bodu
Bodu Mar. 15 at 9:51 PM
$NVAX No proxy fight nor buyout. You want to know where the company is going you just need to listen to what they say. More partnerships , MTA,’s, payments per development milestones and royalties. Respiratory diseases, C. Diff bacteria, Shingles virus, flu, covid, EBV, Malaria and the jewel in the crown Oncology vaccines and treatments. No one believed it one year ago but now it seems to be very straightforward. Do you agree?
1 · Reply
Paulchowda
Paulchowda Mar. 15 at 6:41 PM
$NVAX oh hell, yeah lotta shrinkage on that corn beef, ☘️🇮🇪☘️
1 · Reply
Hoodoo_Voodoo
Hoodoo_Voodoo Mar. 15 at 6:37 PM
$NVAX SMAs stacking, low volume, selling exhausted, high days to cover (8–13+)… calm before the storm. If XBI bounces and it breaks 11.40 with volume acceleration gamma squeeze is on.
1 · Reply
Biotechlineup
Biotechlineup Mar. 15 at 6:18 PM
$NVAX wishing for a proxy fight is a short sellers agenda and Novavax longs nightmare. For a long it’s sort of wishing your house burns down. Only longs with rocks for brains wants that. Would have institutions selling , probably drop about 30%. Nope , I’m long and hoping for a new partnership/ collaboration with another major BP like Merck .Hopefully more than one including oncology. Novavax proprietary CIC is in a immunogenicity phase 3 trial with Top line results in August. If it confirms the preliminary results from June/25 the BP will be lining up to partner. Jacobs in retrospect was correct in turning down a Sanofi low ball offer. It’s Sanofi that’s going to regret that, in fact they already do and fired Hudson with Foard jumping to Merck. French press was critical of the Sanofi missed opportunity .Clarity on Shah backing off is needed , serves zero purpose now. Let’s get to high teens with a mini short squeeze and we will take from there. Bidding war and the true fun begins.
7 · Reply
jerry81
jerry81 Mar. 15 at 3:46 PM
$NVAX I miss those $50 a day gains. Let’s do it again.
1 · Reply
Ochayethenoo
Ochayethenoo Mar. 15 at 1:52 AM
$NVAX https://open.substack.com/pub/maryannedemasi/p/exclusive-leaked-report-to-federal?utm_source=share&utm_medium=android&r=3367il
0 · Reply
BensonFuller
BensonFuller Mar. 14 at 7:14 PM
$NVAX 9 months and Novavax's most valuable asset - the Combo - still sits gathering dust. This should have been partnered last year right after they had the positive results. Now they and any potential partner have missed a full season. This product represents their largest revenue potential. Matrix M deals are great, but revenues are 3 to 4 years out. Hopefully Shah has lost his patience and will initiate the proxy. If anyone here thinks moving from $7.00 to $10.00 will mollify him they are kidding themselves. He has a value of $5 to $10 Billion for the company in an acquisition. It will take years to reach that short of an acquisition. A partnership should get the shares to the mid teens, but there they will sit. Management has FAILED to monetize the Combo. Hopefully Shah can force them to.
5 · Reply
BigCheeze2014
BigCheeze2014 Mar. 14 at 2:21 PM
$NVAX BO…
3 · Reply
DifferentRadar
DifferentRadar Mar. 14 at 12:46 PM
$NVAX Some relevant commentary about a slightly more friendly regulatory environment for the FDA given the fact that a strongly anti-vaccine stance won't serve the current administration well in the coming midterms. https://www.biopharmadive.com/news/gsk-arexvy-fda-approve-rsv-younger-adults/814652/
0 · Reply
BTC321
BTC321 Mar. 14 at 10:37 AM
$NVAX greetings from the côte!
3 · Reply
Latest News on NVAX
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 6:00 PM EDT - 5 days ago

Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 4:22 PM EST - 12 days ago

Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

What's Going On With Novavax Stock On Friday?

Feb 27, 2026, 2:20 PM EST - 16 days ago

What's Going On With Novavax Stock On Friday?

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

Feb 27, 2026, 12:11 PM EST - 16 days ago

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

Novavax to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:30 PM EST - 17 days ago

Novavax to Participate in Upcoming Investor Conferences

Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 3:08 PM EST - 17 days ago

Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript

COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb

Feb 26, 2026, 2:19 PM EST - 17 days ago

COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb

Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals

Feb 26, 2026, 8:06 AM EST - 17 days ago

Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 26, 2026, 8:00 AM EST - 17 days ago

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 19, 2026, 8:00 AM EST - 24 days ago

Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

Jan 30, 2026, 10:09 AM EST - 6 weeks ago

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

MRNA

Novavax Announces Entering into a License Agreement with Pfizer

Jan 20, 2026, 7:15 AM EST - 7 weeks ago

Novavax Announces Entering into a License Agreement with Pfizer

Novavax enters license agreement with Pfizer for vaccine development

Jan 20, 2026, 7:11 AM EST - 7 weeks ago

Novavax enters license agreement with Pfizer for vaccine development

PFE

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 10:15 PM EST - 2 months ago

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 2 months ago

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 3 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

BNTX MRNA PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 3 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

BNTX MRNA PFE

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

Dec 1, 2025, 9:59 AM EST - 3 months ago

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

MRNA

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:33 PM EST - 4 months ago

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Shah Capital pushes for Novavax sale, warns of proxy fight

Nov 12, 2025, 4:41 PM EST - 4 months ago

Shah Capital pushes for Novavax sale, warns of proxy fight

Novavax to Participate in Jefferies London Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 4 months ago

Novavax to Participate in Jefferies London Healthcare Conference

Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:26 PM EST - 4 months ago

Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 8:00 AM EST - 4 months ago

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Novavax raises annual revenue forecast on strength of vaccine deals

Nov 6, 2025, 7:58 AM EST - 4 months ago

Novavax raises annual revenue forecast on strength of vaccine deals

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Nov 4, 2025, 7:00 AM EST - 4 months ago

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Oct 22, 2025, 7:00 AM EDT - 5 months ago

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Oct 14, 2025, 1:08 PM EDT - 5 months ago

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps

Oct 14, 2025, 6:09 AM EDT - 5 months ago

Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Novavax Announces Progress on Sanofi Agreement

Sep 30, 2025, 9:01 AM EDT - 5 months ago

Novavax Announces Progress on Sanofi Agreement

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 6 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

BNTX MRNA PFE

Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 2:10 PM EDT - 6 months ago

Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Novavax to Participate in the Cantor Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Novavax to Participate in the Cantor Global Healthcare Conference

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Aug 27, 2025, 3:07 PM EDT - 7 months ago

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Novavax Announces Convertible Debt Refinancing

Aug 21, 2025, 7:43 AM EDT - 7 months ago

Novavax Announces Convertible Debt Refinancing

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:56 PM EDT - 7 months ago

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Novavax beats quarterly revenue estimates on milestone payment

Aug 6, 2025, 8:08 AM EDT - 7 months ago

Novavax beats quarterly revenue estimates on milestone payment

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 6, 2025, 8:00 AM EDT - 7 months ago

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 8:00 AM EDT - 8 months ago

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Jul 24, 2025, 11:02 AM EDT - 8 months ago

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Jul 24, 2025, 8:00 AM EDT - 8 months ago

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 11, 2025, 8:59 PM EDT - 9 months ago

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Jun 11, 2025, 7:11 AM EDT - 9 months ago

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Jun 11, 2025, 7:00 AM EDT - 9 months ago

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Vaccine actions and policy positions under US Health Secretary Kennedy

Jun 10, 2025, 10:45 AM EDT - 9 months ago

Vaccine actions and policy positions under US Health Secretary Kennedy

BNTX MRNA PFE

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Jun 10, 2025, 9:30 AM EDT - 9 months ago

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

BNTX MRNA PFE

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Jun 10, 2025, 8:18 AM EDT - 9 months ago

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

BNTX MRNA PFE SNY

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

May 21, 2025, 8:15 AM EDT - 10 months ago

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Bodu
Bodu Mar. 15 at 9:51 PM
$NVAX No proxy fight nor buyout. You want to know where the company is going you just need to listen to what they say. More partnerships , MTA,’s, payments per development milestones and royalties. Respiratory diseases, C. Diff bacteria, Shingles virus, flu, covid, EBV, Malaria and the jewel in the crown Oncology vaccines and treatments. No one believed it one year ago but now it seems to be very straightforward. Do you agree?
1 · Reply
Paulchowda
Paulchowda Mar. 15 at 6:41 PM
$NVAX oh hell, yeah lotta shrinkage on that corn beef, ☘️🇮🇪☘️
1 · Reply
Hoodoo_Voodoo
Hoodoo_Voodoo Mar. 15 at 6:37 PM
$NVAX SMAs stacking, low volume, selling exhausted, high days to cover (8–13+)… calm before the storm. If XBI bounces and it breaks 11.40 with volume acceleration gamma squeeze is on.
1 · Reply
Biotechlineup
Biotechlineup Mar. 15 at 6:18 PM
$NVAX wishing for a proxy fight is a short sellers agenda and Novavax longs nightmare. For a long it’s sort of wishing your house burns down. Only longs with rocks for brains wants that. Would have institutions selling , probably drop about 30%. Nope , I’m long and hoping for a new partnership/ collaboration with another major BP like Merck .Hopefully more than one including oncology. Novavax proprietary CIC is in a immunogenicity phase 3 trial with Top line results in August. If it confirms the preliminary results from June/25 the BP will be lining up to partner. Jacobs in retrospect was correct in turning down a Sanofi low ball offer. It’s Sanofi that’s going to regret that, in fact they already do and fired Hudson with Foard jumping to Merck. French press was critical of the Sanofi missed opportunity .Clarity on Shah backing off is needed , serves zero purpose now. Let’s get to high teens with a mini short squeeze and we will take from there. Bidding war and the true fun begins.
7 · Reply
jerry81
jerry81 Mar. 15 at 3:46 PM
$NVAX I miss those $50 a day gains. Let’s do it again.
1 · Reply
Ochayethenoo
Ochayethenoo Mar. 15 at 1:52 AM
$NVAX https://open.substack.com/pub/maryannedemasi/p/exclusive-leaked-report-to-federal?utm_source=share&utm_medium=android&r=3367il
0 · Reply
BensonFuller
BensonFuller Mar. 14 at 7:14 PM
$NVAX 9 months and Novavax's most valuable asset - the Combo - still sits gathering dust. This should have been partnered last year right after they had the positive results. Now they and any potential partner have missed a full season. This product represents their largest revenue potential. Matrix M deals are great, but revenues are 3 to 4 years out. Hopefully Shah has lost his patience and will initiate the proxy. If anyone here thinks moving from $7.00 to $10.00 will mollify him they are kidding themselves. He has a value of $5 to $10 Billion for the company in an acquisition. It will take years to reach that short of an acquisition. A partnership should get the shares to the mid teens, but there they will sit. Management has FAILED to monetize the Combo. Hopefully Shah can force them to.
5 · Reply
BigCheeze2014
BigCheeze2014 Mar. 14 at 2:21 PM
$NVAX BO…
3 · Reply
DifferentRadar
DifferentRadar Mar. 14 at 12:46 PM
$NVAX Some relevant commentary about a slightly more friendly regulatory environment for the FDA given the fact that a strongly anti-vaccine stance won't serve the current administration well in the coming midterms. https://www.biopharmadive.com/news/gsk-arexvy-fda-approve-rsv-younger-adults/814652/
0 · Reply
BTC321
BTC321 Mar. 14 at 10:37 AM
$NVAX greetings from the côte!
3 · Reply
BTC321
BTC321 Mar. 14 at 10:36 AM
$NVAX claude is bullish
1 · Reply
Biotechlineup
Biotechlineup Mar. 14 at 9:56 AM
$NVAX Technically Novavax is still in perfect order. Breakout that started on 12/31/2025 is intact with a bullish expanding ribbon pattern. All indicators positive with institutional investors buying with all support levels holding. Friday the 10 day SMA was challenged and held to maintain perfect order. The 10 pin held. Just to comment on the general market and could use the spy is the exact different direction than Novavax . SPY ( general market) no bullish hammer in fact an ugly bearish Marubozu. Institutional fingerprints indicate increasing selling, don’t listen to any idiot talking head. Clear pre death cross expanding bearish ribbon. If nimble , you can trade it, however for most just a heads up.
1 · Reply
framus_morrigan
framus_morrigan Mar. 14 at 9:00 AM
$NVAX 2-week candles chart updated. The 9.77-11.50 resistance zone is quite tough and we have a lower high for now, but we still have next week to complete that 2-week candle. FWIW that grey dotted line is the 2-week SMA100, last time we were above that moving average was 4 years ago ( I'm sure most of you were less grey by that time 😉 ). Anyway, It's ok as long as the price stays within that ascending channel (mandatorial!) but better for bulls if the current upper wick gets shorter , otherwise that lower high could interpret like a second rejection. GLTA
5 · Reply
Bodu
Bodu Mar. 14 at 8:06 AM
$NVAX The fundamentals. Started the week at $9.68. Finish at $10.24. Its +5.7%. In a week of war. The shorts started the week at 48 million shares after covering 7 million shares in the previous weeks and increased to 50.33 million this week without a great success to stop the Nova train. It looks good. The Novavax fundamentals have changed. Partnership after partnership. Covid, Flu, malaria, cancer, C diff. EBV, Shingles, Pneumonia. Positives are aggregated. It all adds up into a massive pipeline. Massive income minimum expenses. Only RnD. Only design. Stable and growing income from royalties from many customers. Just like the ARM company in cellular phones’ processors. ARM market cap is $150 billion. X100 of Novavax. So this “design house”model is working. And its working well. There is a lot of room to expand. Good luck everyone.
2 · Reply
Chelsea100
Chelsea100 Mar. 14 at 7:25 AM
$NVAX do we have a context with Private Credit Market? This the reason why the share is not falling? Shorts out of money?
0 · Reply
Hoodoo_Voodoo
Hoodoo_Voodoo Mar. 14 at 4:22 AM
$NVAX When can I buy shares of NVAX? This game sucks.
0 · Reply
DragonAlgo
DragonAlgo Mar. 14 at 3:50 AM
🐉 $NVAX CALL — DragonAlgo® Signal Contract: NVAX CALL Expiry: 2026-04-17 | Strike: $9.00 | Type: CALL Option Plan (premium): Entry: $1.78 Stop: $1.28 TP1: $2.31 TP2: $3.03 TP3: $4.27 🔗 https://dragonalgo.com
0 · Reply
Hoodoo_Voodoo
Hoodoo_Voodoo Mar. 14 at 1:26 AM
$NVAX S&P down 1.65% in a week… this up 4.97% All you need to know
0 · Reply
LouAlwaysKnew
LouAlwaysKnew Mar. 14 at 1:00 AM
$NVAX down 7 cents on a Friday We're still above 10 Longs- this ain't nothing
1 · Reply
Imposter333
Imposter333 Mar. 13 at 11:42 PM
$NVAX three words: SHAH NOT COMING.
1 · Reply
DrFUShorts
DrFUShorts Mar. 13 at 9:55 PM
$NVAX Shorts , fake longs and skeptics keep asking me if i'm sure this is going to reach triple digits. My answer is a resounding: I'm triple digits percent sure! If you don't believe me , maybe Ruxy can enlight yourself :)
0 · Reply
avocadro
avocadro Mar. 13 at 9:48 PM
$NVAX For the first time since I started trading this ticker (~9months), it closed in double digits for an entire week, so I am happy. See y’all on Monday! 🍺
0 · Reply